Dapagliflozin Attenuates Renal Tubulointerstitial Fibrosis Associated With Type 1 Diabetes by Regulating STAT1/TGFβ1 Signaling

@inproceedings{Huang2019DapagliflozinAR,
  title={Dapagliflozin Attenuates Renal Tubulointerstitial Fibrosis Associated With Type 1 Diabetes by Regulating STAT1/TGFβ1 Signaling},
  author={Fengjuan Huang and Miss Yanyan Zhao and Qingzhu Wang and Jl Hillebrands and Jacob van den Born and Linlin Ji and Tingting An and Kim Hei-Man Chow},
  booktitle={Front. Endocrinol.},
  year={2019}
}
Tubulointerstitial fibrosis (TIF) plays an important role in the progression of renal fibrosis in diabetic nephropathy (DN). Accumulating evidence supports a crucial inhibitory effect of dapagliflozin, a SGLT2 inhibitor, on TIF, but the underlying mechanisms remain largely unknown. This study aimed to shed light on the efficacy of dapagliflozin in reducing TIF as well as its possible impact on renal function. TIF in human kidney biopsies obtained from patients with DN was quantified by… CONTINUE READING

Similar Papers

References

Publications referenced by this paper.
SHOWING 1-10 OF 33 REFERENCES

Dapagliflozin slows the progression of the renal and liver fibrosis associated with type 2 diabetes.

  • American journal of physiology. Endocrinology and metabolism
  • 2017
VIEW 1 EXCERPT